Sciwind Biosciences has already licensed its GLP-1 obesity drug ecnoglutide twice over — to Pfizer and Verdiva Bio — but it is not done yet.
June 12, 2026 05:00 AM EDTUpdated 10:32 AM
DealsChinaGLP-1 drugs
Sciwind has two Western partners for its obesity drug, but is open to more
Elizabeth Cairns
Senior biopharma journalist
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss…
BrightGene's obesity shot BGM0504 posts strong Phase 3 data in China as it courts a Western partner ahead of a planned global…
Pharmaceutical contractor’s GLP-1 programmes and surging stock gains have made it a magnet for global investors.
Top scientists from have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes.
In China, over 60 late-stage drugs are undergoing clinical trials, and may compete with those from incumbents Novo Nordisk and…
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how…
